KT 433

Drug Profile

KT 433

Latest Information Update: 23 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kotobuki Seiyaku
  • Class Antigouts; Small molecules; Uricosurics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Gout

Most Recent Events

  • 23 Mar 2007 Discontinued - Phase-II for Gout in Japan (PO)
  • 18 Mar 2001 Phase-II clinical trials for Gout in Japan (PO)
  • 20 Oct 1994 Phase-I clinical trials for Gout in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top